XML 78 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 16, 2024
USD ($)
Jul. 31, 2023
USD ($)
Jan. 31, 2023
dose
Jul. 31, 2020
dose
May 31, 2020
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
dose
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 30, 2023
dose
Aug. 31, 2023
USD ($)
Nov. 30, 2022
dose
Nov. 18, 2022
dose
Jul. 31, 2022
USD ($)
dose
Oct. 22, 2020
dose
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Billed contracts receivable             $ 286,400,000 $ 53,800,000              
Unbilled contracts receivable             10,800,000 28,600,000              
Deferred revenue             863,521,000 549,551,000 $ 1,595,472,000            
Purchase agreement, number of vaccine doses | dose                             60,000,000
Deferred revenue, current             241,310,000 370,137,000 1,400,000,000            
Deferred revenue, noncurrent             622,210,000 179,414,000 172,500,000            
Refunds due to APA customers             142,165,000 210,362,000              
Total revenue             983,705,000 1,981,872,000 1,146,290,000            
Sales-Based Royalties                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenue             8,500,000 9,000,000 178,600,000            
Milestone Payments                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenue             0 20,000,000 20,000,000            
Product sales                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred revenue             105,688,000 0              
Increase (decrease) in contract with customer, liability             26,028,000                
Contract value no longer available             131,716,000                
Total revenue             $ 531,389,000 1,554,961,000 0            
Amended and Restated UK Supply Agreement | Minimum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose                           1,000,000  
Amended and Restated UK Supply Agreement | Maximum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose                   0   7,500,000   15,000,000  
Gavi Advance Purchase Agreement SIIPL                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred revenue                 $ 350,000,000            
Number of doses to be distributed | dose             1,100,000,000                
Remaining performance obligation, variable consideration amount               350,000,000              
Gavi Advance Purchase Agreement- COVAX Facility                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose                         350,000,000    
Collaboration agreement upfront payment amount             $ 696,400,000 697,400,000              
Purchase agreement, number of vaccine doses | dose                         2,000,000    
European Commissions ("EC")                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose             100,000,000                
Additional purchase option, number of doses | dose             200,000,000                
Number of doses, cancelled | dose             7,000,000                
Purchase agreement, number of vaccine doses | dose             63,000,000                
Number of doses | dose     20,000,000                        
European Commissions ("EC") | Minimum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose             20,000,000                
European Commissions ("EC") | Maximum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose             100,000,000                
Canada Advance Purchase Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaboration agreement upfront payment amount             $ 100,400,000                
Product sales             349,600,000                
Installment charges   $ 174,800,000         174,800,000                
Deferred revenue, current             102,800,000                
Deferred revenue, noncurrent             $ 485,300,000                
Contract with customer, obligation to deliver, terms             15 years                
Percent of remaining amount to be paid             100.00%                
Escrow to sales hold             $ 20,000,000                
Canada Advance Purchase Agreement | Canada Revenue Agency                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred revenue, current             28,000,000                
Refunds due to APA customers             224,000,000                
Joint Committee on Vaccination and Immunization (JCVI)                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses to be distributed | dose                           44,000,000  
Collaboration agreement upfront payment amount                           $ 225,000,000  
US Government Partnership                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payment recognized             1,800,000,000                
USG Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of doses | dose       100,000,000                      
Coalition for Epidemic Preparedness Innovations ("CEPI")                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Contract to perform for others funding         $ 399,500,000                    
Contract to perform for others grant         257,000,000                    
Contract to perform for others forgivable no interest term loans         $ 142,500,000                    
CEPI Grant Funding                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenue from contract with customer             358,600,000 358,600,000              
Matrix-M Adjuvant Sales                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenue             16,500,000 $ 15,000,000              
Settlement Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred revenue                     $ 4,000,000        
Settlement Agreement | Forecast                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Settlement expense           $ 400,000,000                  
Settlement Agreement | Subsequent Event                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Initial settlement payment $ 75,000,000                            
Settlement expense 80,000,000                            
Grants additional credit $ 225,000,000                            
Australian APA                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred revenue             6,000,000                
Increase (decrease) in contract with customer, liability             64,700,000                
Contract value no longer available             48,000,000                
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Remaining performance obligation to be satisfied             $ 2,000,000,000                
Remaining performance obligation, expected timing of satisfaction, period             1 year